When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ADAP - Adaptimmune's ADP-A2M4 nabs accelerated review in EU for soft tissue cancer
Adaptimmune Therapeutics plc
The European Medicines Agency (EMA) grants PRIME status to Adaptimmune Therapeutics' (NASDAQ:ADAP) lead candidate ADP-A2M4, a SPEAR T-cell therapy, for the treatment of synovial sarcoma, a cancer of soft tissue such as muscle or ligaments. It also has Orphan Drug and Regenerative Medicine Advanced Therapy status for the indication.
More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move,